NZ609363A - Methods for determining anti-drug antibody isotypes - Google Patents

Methods for determining anti-drug antibody isotypes

Info

Publication number
NZ609363A
NZ609363A NZ60936311A NZ60936311A NZ609363A NZ 609363 A NZ609363 A NZ 609363A NZ 60936311 A NZ60936311 A NZ 60936311A NZ 60936311 A NZ60936311 A NZ 60936311A NZ 609363 A NZ609363 A NZ 609363A
Authority
NZ
New Zealand
Prior art keywords
labeled
tnfα drug
autoantibody
isotype
complexes
Prior art date
Application number
NZ60936311A
Other languages
English (en)
Inventor
Shui Long Wang
Linda Ohrmund
Scott Hauenstein
Sharat Singh
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of NZ609363A publication Critical patent/NZ609363A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
NZ60936311A 2010-10-18 2011-10-18 Methods for determining anti-drug antibody isotypes NZ609363A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39426910P 2010-10-18 2010-10-18
PCT/US2011/056777 WO2012054532A1 (en) 2010-10-18 2011-10-18 Methods for determining anti-drug antibody isotypes

Publications (1)

Publication Number Publication Date
NZ609363A true NZ609363A (en) 2015-04-24

Family

ID=45044693

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ60936311A NZ609363A (en) 2010-10-18 2011-10-18 Methods for determining anti-drug antibody isotypes

Country Status (13)

Country Link
US (1) US9784748B2 (es)
EP (1) EP2630495B1 (es)
JP (1) JP5960707B2 (es)
KR (1) KR101934247B1 (es)
CN (1) CN103299190B (es)
AU (1) AU2011317149B2 (es)
BR (1) BR112013009376A2 (es)
CA (1) CA2815026C (es)
IL (1) IL225534A (es)
MX (1) MX344053B (es)
NZ (1) NZ609363A (es)
SG (1) SG189391A1 (es)
WO (1) WO2012054532A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
CA2778454C (en) 2009-10-26 2021-03-02 Prometheus Laboratories Inc. Assays for the detection of anti-tnf drugs and autoantibodies
JP5960707B2 (ja) 2010-10-18 2016-08-02 ネステク ソシエテ アノニム 抗薬物抗体アイソタイプを決定するための方法
CN103782172A (zh) 2011-07-06 2014-05-07 雀巢产品技术援助有限公司 检测针对使用TNFα的生物疗法的中和性自体抗体的测定法
RU2638812C2 (ru) * 2012-03-08 2017-12-15 Ф. Хоффманн-Ля Рош Аг Мультиплексный иммунохроматографический способ определения циркулирующих иммунокомплексов
AU2013326070A1 (en) 2012-10-05 2015-04-23 Société des Produits Nestlé S.A. Methods for predicting and monitoring mucosal healing
BR112015012482A2 (pt) * 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
CN104870982B (zh) * 2012-12-20 2019-02-15 霍夫曼-拉罗奇有限公司 用于评估医学测量曲线的方法
EP2954329A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
US9017958B2 (en) * 2013-03-12 2015-04-28 Bloodcenter Research Foundation, Inc. Method of simultaneous detection of heparin-induced immunoglobulins types G, A, and M
BR112015024752A2 (pt) 2013-03-27 2017-07-18 Cedars Sinai Medical Center mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
CA2932571A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Methods for predicting post-operative recurrence of crohn's disease
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
AU2015356613A1 (en) 2014-12-05 2017-06-15 Société des Produits Nestlé S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
WO2016135707A1 (en) 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
US9927443B2 (en) * 2015-04-10 2018-03-27 Conquerab Inc. Risk assessment for therapeutic drugs
CA2995457A1 (en) 2015-08-13 2017-02-16 Dyax Corp. Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
EP3339862A4 (en) * 2015-08-17 2019-03-13 Sekisui Medical Co., Ltd. IMMUNOLOGICAL PROOF AND TEST STRIP FOR THIS
KR102464372B1 (ko) 2016-03-17 2022-11-04 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
US9903866B2 (en) 2016-04-05 2018-02-27 Conquerab Inc. Portable devices for detection of antibodies against therapeutic drugs
WO2019116234A1 (en) 2017-12-12 2019-06-20 Nestec S.A. Methods for determining microbiome ribosomal rna composition changes
CN110616258A (zh) * 2019-01-24 2019-12-27 上海市第十人民医院 用于检测rs4077515多态性位点的物质在评价或辅助评价ABPA中的应用
CN113474657A (zh) * 2019-02-21 2021-10-01 丁勤学 使用微粒去除非特异性结合信号的方法
KR20220088529A (ko) 2019-05-14 2022-06-27 프로메테우스 바이오사이언시즈, 인크. Tl1a 환자 선택 방법, 시스템 및 장치
EP3990922A1 (en) * 2019-06-25 2022-05-04 ProciseDx Inc. Detection of anti-tnf alpha drug biologics and anti-drug antibodies
WO2023025364A1 (en) * 2021-08-24 2023-03-02 Fida Biosystems Aps A method of determining an immunogenic response characteristic of a chemical substance

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US4459359A (en) 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
FR2590674B1 (fr) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JPH0734015B2 (ja) * 1988-04-25 1995-04-12 和光純薬工業株式会社 微量成分の新規測定法
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
EP0440044A1 (en) 1990-01-31 1991-08-07 Abbott Laboratories Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing
US5094740A (en) 1990-02-16 1992-03-10 Glycomed, Inc. Two-dimensional electrophoretic separation of carbohydrates
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5582998A (en) 1991-06-19 1996-12-10 Boehringer Ingelheim International Gmbh Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
JPH0566222A (ja) * 1991-09-09 1993-03-19 Tosoh Corp 物質の分析方法
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
ATE193601T1 (de) 1993-03-10 2000-06-15 Cedars Sinai Medical Center Verfahren zum selektiven nachweis von perinuklearen anti-neutrophilen cytoplasmischen antikörpern bei ulzerativen kolitis oder primärer sclerotischer cholangitis
JPH07110331A (ja) 1993-09-07 1995-04-25 Wako Pure Chem Ind Ltd ヒト補体価測定方法及びヒト補体価測定用試薬組成物
DE69426223T2 (de) 1993-09-07 2001-05-23 Wako Pure Chem Ind Ltd Verfahren und Reagenz zur Messung der Komplementaktivität
JPH07140144A (ja) 1993-11-19 1995-06-02 S R L:Kk アレルゲン特異的IgE抗体の測定方法および抗原抗体複合体の測定方法
JPH10511846A (ja) 1994-12-28 1998-11-17 ユニバーシティ オブ ケンタッキー ヒトガン胎児性抗原に関連する組換えモノクローナル抗イディオタイプ抗体3h1配列
ATE483975T1 (de) 1996-08-12 2010-10-15 Seikisui Chemical Co Ltd Behälter und kits zur bestimmung von zellfunktionen und verfahren zu deren bestimmung
JP3718435B2 (ja) 1996-08-12 2005-11-24 積水化学工業株式会社 細胞機能測定用容器及び細胞機能測定方法
US6391622B1 (en) 1997-04-04 2002-05-21 Caliper Technologies Corp. Closed-loop biochemical analyzers
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
DE19858777B4 (de) 1998-12-18 2006-07-27 Delta Biotechnology Ltd. Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
JP2004500063A (ja) 1999-12-16 2004-01-08 アムジェン インコーポレイテッド Tnfr/opg様分子およびその使用
FR2806739B1 (fr) 2000-03-27 2005-02-18 Fond Jean Dausset Ceph Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
EP1404712B1 (en) 2000-10-30 2014-06-18 The Regents Of The University Of Michigan Nod2 nucleic acids and proteins
EP1330525B1 (en) 2000-10-30 2012-12-05 The Regents Of The University Of Michigan Nod2 nucleic acids and proteins
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003016909A1 (en) 2001-08-16 2003-02-27 Ludwig Institute For Cancer Research Method for determining protein component in a biological sample
JP2003075443A (ja) * 2001-09-03 2003-03-12 Sekisui Chem Co Ltd 標的物質測定試薬、それを用いた標的物質の測定方法
CN1585778A (zh) 2001-11-12 2005-02-23 默克专利有限公司 修饰的抗-TNFα抗体
AU2002347152A1 (en) 2001-12-05 2003-06-17 Cangene Corporation Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
GB0208817D0 (en) * 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
MXPA05001268A (es) 2002-08-01 2005-10-06 Wyeth Corp Metodos y reactivos relacionados con la inflamacion y apoptosis.
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US7648825B2 (en) 2003-06-20 2010-01-19 University Of Florida Research Foundation, Inc. Biomarkers for differentiating between type 1 and type 2 diabetes
EP1654281A1 (en) 2003-08-01 2006-05-10 Amgen, Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
CA2535804A1 (en) 2003-08-14 2005-03-03 Wyeth Anti-lewis y anti-idiotypic antibodies and uses thereof
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
EP1693671A4 (en) * 2003-10-29 2008-03-19 Eisai R&D Man Co Ltd METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE
CA2549971A1 (en) 2003-11-03 2005-05-12 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
ES2239532B1 (es) * 2004-02-06 2006-11-01 Proyecto De Biomedicina Cima S.L. Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr.
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
EP1769244A4 (en) 2004-06-30 2008-05-14 Dow Kenneth Centocor Inc DETECTION OR MEASUREMENT OF ANTIGEN PROTEIN ANTIBODIES IN BIOLOGICAL TISSUE OR SAMPLES
WO2006012472A1 (en) 2004-07-21 2006-02-02 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
KR20080046135A (ko) 2005-05-20 2008-05-26 제넨테크, 인크. 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
JP2009501913A (ja) 2005-07-21 2009-01-22 ゲンマブ エー/エス Fc受容体と結合する抗体原薬に関する効力アッセイ
WO2007037910A2 (en) * 2005-09-14 2007-04-05 Fred Hutchinson Cancer Research Center Specific removal of activated immune cells
JP2007147367A (ja) 2005-11-25 2007-06-14 Sekisui Chem Co Ltd サイトカイン産生能の測定方法
DE102005057920A1 (de) 2005-12-02 2007-06-28 Strohner, Pavel, Dr. Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben
JP4902674B2 (ja) * 2006-03-09 2012-03-21 エフ.ホフマン−ラ ロシュ アーゲー 抗薬物抗体アッセイ法
US20100130367A1 (en) 2006-07-11 2010-05-27 Drexel University Methods of Quantitatively Assessing Inflammation with Biosensing Nanoparticles
WO2008036802A2 (en) 2006-09-21 2008-03-27 Prometheus Laboratories Inc. Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
US20090035216A1 (en) 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
US20110020840A1 (en) 2008-01-15 2011-01-27 Gerrit Jan Wolbink Method and kits for detecting antibodies against therapeutic antibodies
JP2011513753A (ja) 2008-03-05 2011-04-28 シンギュレックス・インコーポレイテッド 分子の高感度検出の方法および組成物
CA2778454C (en) 2009-10-26 2021-03-02 Prometheus Laboratories Inc. Assays for the detection of anti-tnf drugs and autoantibodies
JP5960707B2 (ja) 2010-10-18 2016-08-02 ネステク ソシエテ アノニム 抗薬物抗体アイソタイプを決定するための方法
RU2013142278A (ru) 2011-02-17 2015-03-27 Нестек С.А. ТЕСТЫ ДЛЯ ДЕТЕКЦИИ АУТОАНТИТЕЛ К АНТИ-TNFα ЛЕКАРСТВЕННЫМ СРЕДСТВАМ
CN103782172A (zh) 2011-07-06 2014-05-07 雀巢产品技术援助有限公司 检测针对使用TNFα的生物疗法的中和性自体抗体的测定法
US20130266963A1 (en) 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
US20140051184A1 (en) 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
US20130295685A1 (en) 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
BR112015012482A2 (pt) 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos

Also Published As

Publication number Publication date
MX344053B (es) 2016-12-02
IL225534A (en) 2017-03-30
CA2815026C (en) 2018-11-20
AU2011317149B2 (en) 2015-05-07
RU2013122871A (ru) 2014-11-27
EP2630495A1 (en) 2013-08-28
WO2012054532A1 (en) 2012-04-26
CA2815026A1 (en) 2012-04-26
AU2011317149A1 (en) 2013-05-02
JP2014500482A (ja) 2014-01-09
CN103299190A (zh) 2013-09-11
US9784748B2 (en) 2017-10-10
SG189391A1 (en) 2013-05-31
EP2630495B1 (en) 2017-02-08
CN103299190B (zh) 2017-02-15
KR20130139289A (ko) 2013-12-20
KR101934247B1 (ko) 2019-01-02
IL225534A0 (en) 2013-06-27
MX2013004305A (es) 2013-08-27
US20130344621A1 (en) 2013-12-26
JP5960707B2 (ja) 2016-08-02
BR112013009376A2 (pt) 2016-07-26

Similar Documents

Publication Publication Date Title
NZ609363A (en) Methods for determining anti-drug antibody isotypes
NZ621655A (en) Assays for the detection of anti-tnf drugs and autoantibodies
PH12017501178A1 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
MX2009013388A (es) Analisis multiple de muestras de sangre.
CA2844033C (en) Method for detecting pancreatic cancer
WO2013074520A3 (en) Detection, isolation and analysis of rare cells in biological fluids
WO2012170435A3 (en) Diagnostic devices, methods and systems for detecting platelet factor 4 (pf4)/heparin antibodies
NZ629703A (en) Methods and compositions for detecting multiple analytes with a single signal
TW200741203A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
FR2935384B1 (fr) Procede de detection du virus de la rougeole, dispositif et kit utilisant ce procede
NZ609824A (en) Immunochromatography devices, methods and kits
WO2012082742A3 (en) Detecting cancer with anti-ccl25 and anti-ccr9 antibodies
SG10201906124XA (en) Foetal nucleated red blood cell detection
ZA202002415B (en) Detection of symmetrical dimethylarginine
RU2020129667A (ru) Способ детектирования молекулы-мишени и набор для использования в этом способе
MX369610B (es) Metodos, dispositivos y sistemas para analisis de muestras.
BR112012025082A8 (pt) Novos anticorpos monoclonais e método de análise imunológica de dímero-d
MY151189A (en) Method of detecting raw pork and detection kit therefor
GB0900151D0 (en) rapid bioluminescence detection system
WO2013106778A3 (en) Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
EP4253950A3 (en) Ce-western applications for antibody development
TW201144810A (en) Kits for RhD blood type determination and method for RhD blood type determination by using the same
MX2018015047A (es) Metodo para la deteccion de un anticuerpo igm especifico para un flavivirus en una muestra.
MY194325A (en) Test object detection method, and immunoassay instrument and monoclonal antibody for same
WO2012018855A3 (en) Systems and methods for immunosorbent assays for single and multiple analytes

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 OCT 2016 BY CPA GLOBAL

Effective date: 20151002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 OCT 2017 BY CPA GLOBAL

Effective date: 20160902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 OCT 2018 BY CPA GLOBAL

Effective date: 20170831

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 OCT 2019 BY CPA GLOBAL

Effective date: 20180907

ASS Change of ownership

Owner name: SOCIA TA DES PRODUITS NESTLA S.A., CH

Effective date: 20190627

LAPS Patent lapsed